Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Trojan‑Horse Siderophore–Teixobactin Conjugates to Defeat Gram‑Negative Superbugs

Project description

A Trojan horse strategy to combat gram-negative antibiotic resistance

Antimicrobial resistance has become a major global health problem, making it difficult to cure even the easily treatable infections. Supported by the Marie Skłodowska-Curie Actions programme, the SYNTH HORSE project aims to tackle the problem of antimicrobial resistance with regard to Gram-negative bacteria such as Acinetobacter baumannii and Pseudomonas aeruginosa that are resistant due to their impermeable outer membrane. This project will create siderophore-teixobactin conjugates that can use the iron transport machinery of the bacterium for delivery of the antibiotic into cells. More precisely, the SYNTH HORSE project will synthesise about 60 conjugates, analyse their anti-microbial activity, resistance capacity and cell uptake as well as determine the most effective candidates against multidrug resistance.

Objective

Antimicrobial resistance (AMR) could cause 10 million deaths annually by 2050, with multidrug-resistant Gram-negative pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa listed by WHO as critical priorities. Current antibiotics fail against these species because their outer membrane blocks entry. Teixobactin, discovered in 2015, kills Gram-positive bacteria without resistance by binding the highly conserved lipid II motif, but it cannot reach this target in Gram-negatives.

SYNTH-HORSE introduces a first-in-class strategy: siderophore–teixobactin conjugates (STCs). By hijacking bacterial iron-uptake pathways—the clinically validated “Trojan Horse” mechanism—STCs deliver resistance-avoidant teixobactins into Gram-negative cells. The project will: (i) synthesise ~60 STCs across diverse teixobactin analogues, siderophores (catecholate, MECAM, DOTAM) and linkers; (ii) test antibacterial potency, bactericidal activity and resistance frequency; and (iii) validate uptake and lipid II engagement. By month 24, ≥10 optimised STCs will be delivered to tackle MDR Gram negative bacteria.

The fellowship combines cutting-edge chemistry, microbiology, and industrial translation. Hosted at the University of Liverpool (leaders in synthetic teixobactins), with a 5-month secondment at HZI Germany (antibiotic uptake biology) and training at Bachem UK (green peptide synthesis, scale-up), the Fellow will gain unique interdisciplinary, intersectoral, and international (3i) expertise. Outcomes include IP-ready leads, FAIR/Green Charter-aligned workflows, high-impact publications, and wide dissemination from science to policy.
Impact: SYNTH-HORSE delivers a breakthrough Gram-negative antibiotic platform, transforms the researcher into a future AMR leader, and contributes to EU missions on health, innovation, and sustainability.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-PF

See all projects funded under this call

Coordinator

THE UNIVERSITY OF LIVERPOOL
Net EU contribution
€ 276 187,92
Address
BROWNLOW HILL 765 FOUNDATION BUILDING
L69 7ZX LIVERPOOL
United Kingdom
Region
North West (England) Merseyside Liverpool
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (1)